Kantarjian H., Kadia T., DiNardo C., Daver N., Borthakur G., Jabbour E., Garcia-Manero G., Konopleva M., Ravandi F. 2021. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 11, 41. https://doi.org/10.1038/s41408-021-00425-3

Article  PubMed  PubMed Central  Google Scholar 

Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L., Weiss W.A. 2016. Neuroblastoma. Nat. Rev. Dis. Primers. 2, 16078. https://doi.org/10.1038/nrdp.2016.78

Article  PubMed  Google Scholar 

Koshy M., Villano J.L., Dolecek T.A., Howard A., Mahmood U., Chmura S.J., Weichselbaum R.R., M-cCarthy B.J. 2012. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neurooncol. 107, 207–212. https://doi.org/10.1007/s11060-011-0738-7

Article  PubMed  Google Scholar 

Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O., European Organisation for R., Treatment of Cancer Brain T., Radiotherapy G., National Cancer Institute of Canada Clinical Trials G. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996. https://doi.org/10.1056/NEJMoa043330

Article  CAS  PubMed  Google Scholar 

Tan A.C., Ashley D.M., Lopez G.Y., Malinzak M., Friedman H.S., Khasraw M. 2020. Management of glioblastoma: State of the art and future directions. CA Cancer J. Clin. 70, 299–312. https://doi.org/10.3322/caac.21613

Article  PubMed  Google Scholar 

Vijayaraghavalu S., Dermawan J.K., Cheriyath V., Labhasetwar V. 2013. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol. Pharm. 10, 337–352. https://doi.org/10.1021/mp3004622

Article  CAS  PubMed  Google Scholar 

Housman G., Byler S., Heerboth S., Lapinska K., Longacre M., Snyder N., Sarkar S. 2014. Drug resistance in cancer: an overview. Cancers (Basel). 6, 1769–1792. https://doi.org/10.3390/cancers6031769

Article  PubMed  PubMed Central  Google Scholar 

Qiu T., Zhou L., Zhu W., Wang T., Wang J., Shu Y., Liu P. 2013. Effects of treatment with histone deacetylase inhibitors in solid tumors: A review based on 30 clinical trials. Future Oncol. 9, 255–269. https://doi.org/10.2217/fon.12.173

Article  CAS  PubMed  Google Scholar 

Tyner J.W., Tognon C.E., Bottomly D., Wilmot B., Kurtz S.E., Savage S.L., Long N., Schultz A.R., Traer E., Abel M., Agarwal A., Blucher A., Borate U., Bryant J., Burke R., Carlos A., Carpenter R., Carroll J., Chang B.H., Coblentz C., d’Almeida A., Cook R., Danilov A., Dao K.T., Degnin M., Devine D., Dibb J., Edwards D.K.t., Eide C.A., English I., Glover J., Henson R., Ho H., Jemal A., Johnson K., Johnson R., Junio B., Kaempf A., Leonard J., Lin C., Liu S.Q., Lo P., Loriaux M.M., Luty S., Macey T., MacManiman J., Martinez J., Mori M., Nelson D., Nichols C., Peters J., Ramsdill J., Rofelty A., Schuff R., Searles R., Segerdell E., Smith R.L., Spurgeon S.E., Sweeney T., Thapa A., Visser C., Wagner J., Watanabe-Smith K., Werth K., Wolf J., White L., Yates A., Zhang H., Cogle C.R., Collins R.H., Connolly D.C., Deininger M.W., Drusbosky L., Hourigan C.S., Jordan C.T., Kropf P., Lin T.L., Martinez M.E., Medeiros B.C., Pallapati R.R., Pollyea D.A., Swords R.T., Watts J.M., Weir S.J., Wiest D.L., Winters R.M., McWeeney S.K., Druker B.J. 2018. Functional genomic landscape of acute myeloid leukaemia. Nature. 562, 526–531. https://doi.org/10.1038/s41586-018-0623-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., Van Vlierberghe P., Dolgalev I., Thomas S., Aminova O., Huberman K., Cheng J., Viale A., Socci N.D., Heguy A., Cherry A., Vance G., Higgins R.R., Ketterling R.P., Gallagher R.E., Litzow M., van den Brink M.R., Lazarus H.M., Rowe J.M., Luger S., Ferrando A., Paietta E., Tallman M.S., Melnick A., Abdel-Wahab O., Levine R.L. 2012. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089. https://doi.org/10.1056/NEJMoa1112304

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V.I., Paschka P., Roberts N.D., Potter N.E., Heuser M., Thol F., Bolli N., Gundem G., Van Loo P., Martincorena I., Ganly P., Mudie L., McLaren S., O’Meara S., Raine K., Jones D.R., Teague J.W., Butler A.P., Greaves M.F., Ganser A., Dohner K., Schlenk R.F., Dohner H., Campbell P.J. 2016. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221. https://doi.org/10.1056/NEJMoa1516192

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Research N., Ley T.J., Miller C., Ding L., Raphael B.J., Mungall A.J., Robertson A., Hoadley K., Triche T.J., Jr., Laird P.W., Baty J.D., Fulton L.L., Fulton R., Heath S.E., Kalicki-Veizer J., Kandoth C., Klco J.M., Koboldt D.C., Kanchi K.L., Kulkarni S., Lamprecht T.L., Larson D.E., Lin L., Lu C., McLellan M.D., McMichael J.F., Payton J., Schmidt H., Spencer D.H., Tomasson M.H., Wallis J.W., Wartman L.D., Watson M.A., Welch J., Wendl M.C., Ally A., Balasundaram M., Birol I., Butterfield Y., Chiu R., Chu A., Chuah E., Chun H.J., Corbett R., Dhalla N., Guin R., He A., Hirst C., Hirst M., Holt R.A., Jones S., Karsan A., Lee D., Li H.I., Marra M.A., Mayo M., Moore R.A., Mungall K., Parker J., Pleasance E., Plettner P., Schein J., Stoll D., Swanson L., Tam A., Thiessen N., Varhol R., Wye N., Zhao Y., Gabriel S., Getz G., Sougnez C., Zou L., Leiserson M.D., Vandin F., Wu H.T., Applebaum F., Baylin S.B., Akbani R., Broom B.M., Chen K., Motter T.C., Nguyen K., Weinstein J.N., Zhang N., Ferguson M.L., Adams C., Black A., Bowen J., Gastier-Foster J., Grossman T., Lichtenberg T., Wise L., Davidsen T., Demchok J.A., Shaw K.R., Sheth M., Sofia H.J., Yang L., Downing J.R., Eley G. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074. https://doi.org/10.1056/NEJMoa1301689

Article  CAS  Google Scholar 

Christman J.K. 2002. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 21, 5483–5495. https://doi.org/10.1038/sj.onc.1205699

Article  CAS  PubMed  Google Scholar 

Estey E.H. 2013. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 27, 1803–1812. https://doi.org/10.1038/leu.2013.173

Article  CAS  PubMed  Google Scholar 

Bartolucci S., Estenoz M., Longo A., Santoro B., Momparler R.L., Rossi M., Augusti-Tocco G. 1989. 5‑Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. Cell Differ Dev. 27, 47–55. https://doi.org/10.1016/0922-3371(89)90043-9

Article  CAS  PubMed  Google Scholar 

Carpinelli P., Granata F., Augusti-Tocco G., Rossi M., Bartolucci S. 1993. Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines. Anticancer Drugs. 4, 629–635. https://doi.org/10.1097/00001813-199312000-00004

Article  CAS  PubMed  Google Scholar 

Charlet J., Schnekenburger M., Brown K.W., Diederich M. 2012. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem. Pharmacol. 83, 858–865. https://doi.org/10.1016/j.bcp.2012.01.009

Article  CAS  PubMed  Google Scholar 

Lipatova A.V., Soboleva A.V., Gorshkov V.A., Bubis J.A., Solovyeva E.M., Krasnov G.S., Kochetkov D.V., Vorobyev P.O., Ilina I.Y., Moshkovskii S.A., Kjeldsen F., Gorshkov M.V., Chumakov P.M., Tarasova I.A. 2021. Multi-omics analysis of glioblastoma cells’ sensitivity to oncolytic viruses. Cancers (Basel). 13 (21), 5268. https://doi.org/10.3390/cancers13215268

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khandazhinskaya A.L., Alexandrova L.A., Matyugina E.S., Solyev P.N., Efremenkova O.V., Buckheit K.W., Wilkinson M., Buckheit R.W., Jr., Chernousova L.N., Smirnova T.G., Andreevskaya S.N., Leonova O.G., Popenko V.I., Kochetkov S.N., Seley-Radtke K.L. 2018. Novel 5'-norcarbocyclic pyrimidine derivatives as antibacterial agents. Molecules. 23 (12), 3069. https://doi.org/10.3390/molecules23123069

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kezin V.A., Matyugina E.S., Novikov M.S., Chizhov A.O., Snoeck R., Andrei G., Kochetkov S.N., Khandazhinskaya A.L. 2022. New derivatives of 5-substituted uracils: Potential agents with a wide spectrum of biological activity. Molecules. 27 (9), 2866. https://doi.org/10.3390/molecules27092866

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carbon J., David H., Studier M.H. 1968. Thiobases in Escherchia coli transfer RNA: 2-Thiocytosine and 5-methylaminomethyl-2-thiouracil. Science. 161, 1146–1147. https://doi.org/10.1126/science.161.3846.1146

Article  CAS  PubMed  Google Scholar 

Orr G.F., Musso D.L., Boswell G.E., Kelley J.L., Joyner S.S., Davis S.T., Baccanari D.P. 1995. Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. J. Med. Chem. 38, 3850–3856. https://doi.org/10.1021/jm00019a015

Article  CAS  PubMed  Google Scholar 

el Kouni M.H., el Kouni M.M., Naguib F.N. 1993. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res. 53, 3687–3693.

CAS  PubMed  Google Scholar 

Roth B., Aig E., Lane K., Rauckman B.S. 1980. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 4. 6-Substituted trimethoprim derivatives from phenolic Mannich intermediates. Application to the synthesis of trimethoprim and 3,5-dialkylbenzyl analogues. J. Med. Chem. 23, 535–541. https://doi.org/10.1021/jm00179a012

Article  CAS  PubMed  Google Scholar 

Orr G.F., Musso D.L., Kelley J.L., Joyner S.S., Davis S.T., Baccanari D.P. 1997. Inhibition of uridine phosphorylase. Synthesis and structure-activity rela-tionships of aryl-substituted 1-((2-hydroxyetho-xy)methyl)-5-(3-phenoxybenzyl)uracil. J. Med. Chem. 40, 1179–1185. https://doi.org/10.1021/jm960688j

Article  CAS  PubMed  Google Scholar 

Chowdhury S.F., Villamor V.B., Guerrero R.H., Leal I., Brun R., Croft S.L., Goodman J.M., Maes L., Ruiz Perez L.M., Pacanowska D.G., Gilbert I.H. 1999. Design, synthesis, and evaluation of inhibitors of try-panosomal and leishmanial dihydrofolate reductase. J. Med. Chem. 42, 4300–4312. https://doi.org/10.1021/jm981130+

Article  CAS  PubMed  Google Scholar 

Nencka R., Votruba I., Hrebabecky H., Jansa P., Tloust’ova E., Horska K., Masojidkova M., Holy A. 2007. Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J. Med. Chem. 50, 6016–6023. https://doi.org/10.1021/jm070644i

Article  CAS  PubMed  Google Scholar 

Novikov M.S., Buckheit R.W., Jr., Temburnikar K., Khandazhinskaya A.L., Ivanov A.V., Seley-Radtke K.L. 2010. 1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents. Bioorg. Med. Chem. 18, 8310–8314. https://doi.org/10.1016/j.bmc.2010.09.070

Article  CAS